Physiology · PeptideU · 7 min read

Deruxtecan: Physiology and What Research Reports

The short answer

Deruxtecan is not a peptide hormone and is not made in the body. It is the synthetic cytotoxic payload — a topoisomerase I inhibitor — joined to an antibody by a cleavable tetrapeptide-based linker, most familiar as part of trastuzumab deruxtecan, an antibody–drug conjugate studied in HER2-expressing cancers. Published phase 2 and phase 3 trials reported tumour response and progression-free survival outcomes alongside nausea, cytopenias and interstitial lung disease. This page summarises what those studies described, and nothing more.

What deruxtecan is

Deruxtecan is a term readers often meet without context, usually as the second half of the compound name trastuzumab deruxtecan. It is not an endogenous peptide, not a growth factor, and not a research peptide in the sense that word is usually used. Deruxtecan refers to the payload–linker portion of an antibody–drug conjugate (ADC): a synthetic small molecule that inhibits topoisomerase I, attached to a monoclonal antibody through a cleavable tetrapeptide-based linker, as described in the approval review of trastuzumab deruxtecan (PMID 32144719).

The peptide chemistry inside the molecule

The word "tetrapeptide" is the reason this molecule turns up in peptide reading lists. A tetrapeptide is simply four amino acids joined by peptide bonds. In this design the short peptide sequence acts as a chemical hinge: it is stable while the conjugate circulates and is designed to be cleaved by enzymes inside the target cell, releasing the topoisomerase I inhibitor payload. The approval review described trastuzumab deruxtecan as an anti-HER2 antibody joined to that payload by a cleavable tetrapeptide-based linker (PMID 32144719). Peptide bonds here are structural engineering, not signalling.

Where it comes from and what it does in the body

Deruxtecan is manufactured, not secreted. There is no gland, tissue or feedback loop that produces it. Its biological behaviour is entirely a function of the conjugate it belongs to: the antibody component determines which cells the molecule sticks to, and the peptide linker determines when the payload is let go. A review of trastuzumab deruxtecan in breast cancer described this architecture — antibody targeting of HER2, internalisation, intracellular linker cleavage, and release of a membrane-permeable topoisomerase I inhibitor payload capable of affecting neighbouring cells — as the basis for activity across a range of HER2 expression levels (PMID 38621469).

How it is measured and studied

Deruxtecan is not measured in healthy physiology the way a hormone is. In clinical research it is studied as part of the intact conjugate, with laboratories quantifying the antibody, the conjugate and the released payload separately, and with tumour HER2 status measured by immunohistochemistry and in-situ hybridisation. That tissue measurement defines the study populations: researchers in the HER2-low advanced breast cancer trial enrolled patients whose tumours scored immunohistochemistry 1+ or 2+ without gene amplification (PMID 35665782). Trial endpoints are oncology endpoints — objective response rate, progression-free survival and overall survival — rather than physiological markers, and lung safety has been assessed by independent adjudication of interstitial lung disease events (PMID 35320644).

Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.

Try it free

What the literature reports

The earliest large report, a phase 2 study in previously treated HER2-positive breast cancer, enrolled 184 patients who received 5.4 mg/kg every three weeks and reported an objective response in 60.9% with median progression-free survival of 16.4 months (PMID 31825192). A parallel randomised phase 2 study in previously treated HER2-positive gastric cancer used 6.4 mg/kg every three weeks and reported a response in 51% of patients versus 14% with chemotherapy, with median overall survival of 12.5 versus 8.4 months (PMID 32469182).

Randomised phase 3 work followed. The study comparing trastuzumab deruxtecan with trastuzumab emtansine reported 12-month progression-free survival of 75.8% versus 34.1% (PMID 35320644), and the updated analysis of that trial reported median progression-free survival of 28.8 versus 6.8 months (PMID 36495879). Against treatment of physician's choice, researchers reported median progression-free survival of 17.8 versus 6.9 months (PMID 37086745).

Setting studied	What researchers reported
HER2-low advanced breast cancer, previously treated	Median progression-free survival 9.9 versus 5.1 months and overall survival 23.4 versus 16.8 months in the hormone-receptor-positive cohort (PMID 35665782)
After endocrine therapy, HER2-low and HER2-ultralow disease	Median progression-free survival 13.2 versus 8.1 months in the HER2-low population (PMID 39282896)
HER2-mutant non-small-cell lung cancer	6.4 mg/kg every three weeks, confirmed response 55%, median progression-free survival 8.2 months (PMID 34534430)
Second-line HER2-positive gastric cancer	Longer overall survival than ramucirumab plus paclitaxel (PMID 40454632)
First-line HER2-positive metastatic breast cancer with pertuzumab	Longer progression-free survival than taxane-based chemotherapy with trastuzumab and pertuzumab (PMID 41160818)

Adverse Events: What Studies Report

Safety reporting is consistent across the programme. In the phase 2 breast cancer study, researchers reported nausea, alopecia, vomiting, constipation, decreased neutrophil count, anaemia and fatigue among the most common adverse events (PMID 31825192). The gastric cancer study reported decreased neutrophil, platelet and white-cell counts and anaemia as the most frequent grade 3 or higher events (PMID 32469182).

Interstitial lung disease has been the event of particular attention. The phase 2 breast cancer study reported drug-related interstitial lung disease in 13.6% of patients, including four fatal cases (PMID 31825192). The randomised comparison with trastuzumab emtansine reported adjudicated drug-related interstitial lung disease in 10.5% of the trastuzumab deruxtecan group with no grade 4 or 5 events (PMID 35320644), while the HER2-low trial reported such events in 12.1% of patients, with 0.8% graded 5 (PMID 35665782). The highest figure in the verified literature came from the HER2-mutant lung cancer study, where interstitial lung disease was reported in 26% of patients (PMID 34534430). These events were recorded in supervised oncology trials with imaging surveillance and protocol-defined management.

Tracking research? Log entries with dates, lots and notes — records, never plans.

Get the app

Why the term matters to peptide readers

Three reasons. First, it is a clear illustration that peptide bonds do more than build hormones — here a four-amino-acid sequence functions as a protease-sensitive release switch inside a targeted drug (PMID 32144719). Second, it shows how linker chemistry, not just the active molecule, shapes where and when an effect occurs (PMID 38621469). Third, and most practically, deruxtecan is a component of an approved intravenous oncology medicine studied in patients with cancer (PMID 32144719). It belongs to a completely different category from the metabolic or repair-oriented peptides that dominate general peptide literature, and the two should not be read as interchangeable.

Limitations of the current literature

The evidence base is oncology-specific: participants had advanced or metastatic cancer, endpoints were tumour and survival outcomes, and comparators were other cancer therapies. Nothing in the verified literature examined deruxtecan in healthy volunteers, and no study cited here reported on performance, recovery or longevity outcomes. Results are also setting-dependent — progression-free survival figures differed by tumour type, prior treatment and HER2 expression level, as the HER2-low and HER2-ultralow analysis illustrated (PMID 39282896).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision. It summarises what published studies reported and does not recommend any product or protocol.

Want the full course? Every compound, evidence-graded and cited, inside PeptideU.

Start learning free

References

Frequently asked questions

Is deruxtecan a peptide?▾

No. Deruxtecan is a synthetic topoisomerase I inhibitor payload, and the peptide element is the linker that joins it to an antibody. The approval review described trastuzumab deruxtecan as an anti-HER2 antibody connected to that payload through a cleavable tetrapeptide-based linker (PMID 32144719). The peptide portion is structural chemistry, not a signalling hormone.

What is deruxtecan used for in published studies?▾

Published studies examined it as part of trastuzumab deruxtecan in HER2-expressing cancers. Trials covered previously treated HER2-positive breast cancer (PMID 31825192), HER2-low advanced breast cancer (PMID 35665782), HER2-positive gastric cancer (PMID 32469182), and HER2-mutant non-small-cell lung cancer (PMID 34534430). All participants had advanced or metastatic malignancy, not healthy physiology.

What doses did the trials use?▾

Dose varied by tumour type in the published protocols. The phase 2 breast cancer study administered 5.4 mg/kg intravenously every three weeks (PMID 31825192), while the gastric cancer study (PMID 32469182) and the HER2-mutant lung cancer study (PMID 34534430) both used 6.4 mg/kg every three weeks. These were investigator-administered regimens in supervised oncology trials.

What adverse events did studies report?▾

Researchers reported nausea, alopecia, vomiting, constipation, fatigue, anaemia and decreased neutrophil counts as common events (PMID 31825192), with cytopenias most frequent among higher-grade events in gastric cancer (PMID 32469182). Interstitial lung disease was reported in 13.6% of patients in the phase 2 breast cancer study, including four fatal cases (PMID 31825192).

How often was interstitial lung disease reported?▾

Rates differed across trials. Adjudicated drug-related interstitial lung disease was reported in 10.5% of the trastuzumab deruxtecan group versus trastuzumab emtansine, with no grade 4 or 5 events (PMID 35320644), in 12.1% in HER2-low breast cancer with 0.8% graded 5 (PMID 35665782), and in 26% of patients with HER2-mutant lung cancer (PMID 34534430).

How do randomised trials compare deruxtecan-based therapy with other treatments?▾

Randomised phase 3 studies reported longer progression-free survival than trastuzumab emtansine, with 12-month rates of 75.8% versus 34.1% (PMID 35320644) and updated medians of 28.8 versus 6.8 months (PMID 36495879). Against treatment of physician's choice, researchers reported median progression-free survival of 17.8 versus 6.9 months (PMID 37086745).

Why does an oncology drug appear in a peptide physiology library?▾

Because readers encounter the word "deruxtecan" and the description "tetrapeptide-based linker" together and reasonably ask what the peptide part does (PMID 32144719). Reviews described the linker as the release mechanism that determines where the payload acts (PMID 38621469). The term belongs to targeted cancer pharmacology, a separate category from general peptide research.

The PeptideU app

Track it. Calculate it. Actually understand it.

Research trackerLog every entry with dates, lots and notes — records, never plans.

CalculatorsReconstitution, units and dilution maths without the guesswork.

The UniversityEvery compound explained, evidence-graded, cited to the literature.

Get started freePeptideU Premium — $9.99/mo for the full curriculum, advanced tracking & giveaways

Download on theApp Store — Free

References

Keep learning

Zilucoplan: Physiology and What Research Reports

18+ · Educational purposes only
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.